Pipeline
At Novavax, we leverage our science, our technology and our people to innovate and collaborate in the fight against some of the world’s most significant health challenges.
All of our assets are built using our protein-based nanoparticles and proprietary Matrix-M® adjuvant technology platform.
Starting with our core expertise in infectious disease, we are also investigating other therapeutic areas where we believe our technology could augment and improve upon current therapies.
Scientific rationale, the ability to reach rapid proof-of-concept, unmet medical need and attractiveness to potential partners are what drive our pipeline prioritization.
Vaccines that contain Novavax technology, commercialized in key markets around the world by our partners
* Authorized in select geographies under trade name Nuvaxovid™
** Commercialized by Serum Institute of India. Granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.
In addition to early and late-stage vaccines developed by Novavax, we continue working on expanding the utility of our Matrix-M adjuvant and creating additional potential Matrix-based adjuvants.
* Approved by Novavax to move to Phase 1/2a by 2027
** Available for partnership; no current investment
We're seeing significant expansion of vaccine pipeline assets that include Novavax technology via our partnering approach. The graphic below represents all disclosed partnerships. Novavax now has general MTA collaborations and/or license agreements providing access to explore Matrix-M in indications across both infectious diseases and oncology.
* NCT06695117 Granted Fast Track designation in the U.S.